Guidelines for the use of palivizumab in infants and young children with congenital heart disease.
Nakazawa
Makoto
M
Guideline Preparation and Review Committee, Heart Institute of Japan, Tokyo Women's Medical University, Tokyo, Japan.
Saji
Tsutomu
T
Ichida
Fukiko
F
Oyama
Kotaro
K
Harada
Kensuke
K
Kusuda
Satoshi
S
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002675:Child, Preschool; D015897:Comorbidity; D004347:Drug Interactions; D006330:Heart Defects, Congenital / Q000453:epidemiology*; D006801:Humans; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000453:epidemiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab